Takashi Kurosaki1, Hisato Kawakami2, Seiichiro Mitani1, Ryohei Kawabata3, Takayuki Takahama4, Yoshikane Nonagase5, Soichi Fumita1, Tomohiro Ozaki5, Yasutaka Chiba6, Takao Tamura4, Kazuhiko Nakagawa1. 1. Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 2. Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan kawakami_h@med.kindai.ac.jp. 3. Department of Surgery, Osaka Rosai Hospital, Sakai, Japan. 4. Department of Medical Oncology, Kindai University Nara Hospital, Ikoma, Japan. 5. Department of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan. 6. Clinical Research Center, Kindai University Hospital, Osaka-Sayama, Japan.
Abstract
BACKGROUND/AIM: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC). PATIENTS AND METHODS: AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab. RESULTS: Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival. CONCLUSION: We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation. Copyright
BACKGROUND/AIM: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC). PATIENTS AND METHODS: AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab. RESULTS: Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival. CONCLUSION: We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation. Copyright
Authors: S Demaria; M D Volm; R L Shapiro; H T Yee; R Oratz; S C Formenti; F Muggia; W F Symmans Journal: Clin Cancer Res Date: 2001-10 Impact factor: 12.531
Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: Donald C McMillan; Joseph E M Crozier; Khalid Canna; Wilson J Angerson; Colin S McArdle Journal: Int J Colorectal Dis Date: 2007-01-24 Impact factor: 2.571